Ionis Pharmaceuticals
IONS
356 hedge funds and large institutions have $6.83B invested in Ionis Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 120 increasing their positions, 132 reducing their positions, and 53 closing their positions.
250% more call options, than puts
Call options by funds: $117M | Put options by funds: $33.5M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
11% more capital invested
Capital invested by funds: $6.17B → $6.83B (+$657M)
0.6% more ownership
Funds ownership: 97.56% → 98.16% (+0.6%)
2% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 53
9% less repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 132
1% less funds holding
Funds holding: 361 → 356 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$57.9M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$51.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$44.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$35.8M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$31.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$94.6M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$54.5M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$54.4M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$29.9M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$27.8M |
IONS Hedge Fund Activity: Q2 2024 in Review
356 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2024, worth a combined $6.83B — up 11% from $6.17B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of IONS and 52 opened new positions — a net loss of 1 holder — while 132 trimmed existing stakes and 120 added.
The largest buyer was Capital World Investors, adding an estimated $57.9M. The largest seller was ClearBridge Investments, cutting an estimated $94.6M.
- 356 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2024, down from 361 in Q1 2024.
- Funds reported $6.83B of Ionis Pharmaceuticals stock for Q2 2024, up 11% quarter-over-quarter.
- 52 funds opened new Ionis Pharmaceuticals positions in Q2 2024 and 53 closed out, a net change of -1 holder.
- The largest Ionis Pharmaceuticals buyer in Q2 2024 was Capital World Investors, an estimated $57.9M added.
- The largest Ionis Pharmaceuticals seller in Q2 2024 was ClearBridge Investments, an estimated $94.6M sold.
Based on aggregated 13F filings for Q2 2024.